Scarica l'app Stockscreener
12.84
0.93%
-0.12
Dopo l'orario di chiusura:
12.85
0.010
+0.08%
Uniqure N V Borsa (QURE) Ultime notizie
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
uniQure (QURE) Expected to Announce Earnings on Wednesday - MarketBeat
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Yahoo Finance
24,749 Shares in uniQure (NASDAQ:QURE) Acquired by Palumbo Wealth Management LLC - MarketBeat
uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
(QURE) Proactive Strategies - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Price Down 6.7%Should You Sell? - MarketBeat
uniQure (NASDAQ:QURE) Raised to Sell at StockNews.com - MarketBeat
abrdn plc Sells 419,726 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Swelling losses haven't held back gains for uniQure (NASDAQ:QURE) shareholders since they're up 147% over 1 year - Simply Wall St
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsuniQure (NASDAQ:QURE), CSL (OTC:CSLLY) - Benzinga
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - Quantisnow
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Analysts Set uniQure (NASDAQ:QURE) Price Target at $40.00 - MarketBeat
uniQure Announces Completion of Enrollment in the First - GlobeNewswire
UniQure Advances AMT-191 Trial in Fabry Disease -February 03, 2025 at 12:09 pm EST - Marketscreener.com
uniQure advances gene therapy trial for Fabry disease By Investing.com - Investing.com Australia
uniQure advances gene therapy trial for Fabry disease - Investing.com
Rare Disease Breakthrough: Gene Therapy Trial Shows Promise in Fabry Disease Treatment - StockTitan
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - The Manila Times
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Issues Negative Estimate for uniQure Earnings - MarketBeat
Analysts Set Expectations for uniQure FY2029 Earnings - MarketBeat
uniQure (NASDAQ:QURE) Trading Down 4.8%Should You Sell? - MarketBeat
uniQure Announces Favorable Recommendation from Independent - GlobeNewswire
UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis - Marketscreener.com
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - The Manila Times
Game-Changing ALS Treatment: uniQure's Gene Therapy Hits Critical Milestone - StockTitan
FY2024 EPS Estimates for uniQure Reduced by HC Wainwright - Defense World
FY2029 Earnings Forecast for uniQure Issued By HC Wainwright - Defense World
HC Wainwright Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price - Defense World
H.C. Wainwright sets uniQure stock price target at $70 By Investing.com - Investing.com Australia
The Hidden Gem in Biotechnology? It’s Time to Take Notice - Jomfruland.net
Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts? - Insider Monkey
H.C. Wainwright sets uniQure stock price target at $70 - Investing.com India
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
12 Most Promising Growth Stocks According to Wall Street Analysts - Insider Monkey
Assenagon Asset Management S.A. Sells 197,775 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Analysts Offer Predictions for uniQure FY2025 Earnings - Defense World
Brokers Offer Predictions for uniQure FY2025 Earnings - MarketBeat
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):